Biogen Inc.'s Stock Analysis

Biogen Chair Caroline Dorsa to Retire from Board in 2026

Caroline Dorsa, Chair of Biogen's Board of Directors, has announced that she will not seek re-election at the 2026 Annual Meeting of Stockholders. Her decision is not due to any disagreements regarding the company's operations or policies.

Following Dorsa's announcement, the Board has elected Dr. Maria C. Friere to take over as Chair effective after the Annual Meeting. This leadership transition may impact the company's governance structure moving forward.

Feb 11, 2026 17:07:38

Biogen Reports Q4 2025 Financial Results and 2026 Guidance

Biogen announced its financial results for the fourth quarter and full year 2025, reporting total revenue of $2.3 billion for Q4 and $9.9 billion for the full year. The company recorded a GAAP diluted EPS of $(0.33) for Q4 and $8.79 for the full year, with Non-GAAP diluted EPS of $1.99 for Q4 and $15.28 for the full year, surpassing previous guidance. Growth products contributed significantly, with LEQEMBI sales increasing 54% year-over-year. However, revenue from multiple sclerosis products, excluding VUMERITY, experienced declines, impacting overall revenue performance.

For 2026, Biogen provided financial guidance expecting Non-GAAP diluted EPS to range between $15.25 and $16.25, while total revenue is anticipated to decline by a mid-single-digit percentage compared to 2025. The company highlighted ongoing progress in its late-stage pipeline, including FDA Priority Review for LEQEMBI IQLIK and Breakthrough Therapy Designation for litifilimab. As of year-end 2025, Biogen had approximately $4.2 billion in cash and cash equivalents and $6.3 billion in total debt.

Feb 06, 2026 06:55:01

Biogen Reports $222 Million Expense Impacting Q4 2025 Earnings

Biogen Inc. anticipates a pre-tax expense of approximately $222 million related to acquired in-process research and development, upfront, and milestone expenses for the fourth quarter of 2025. This charge is expected to reduce both GAAP and non-GAAP net income per diluted share by about $1.26 for the quarter.

The company began presenting these expenses as a separate line item in its financial statements starting in the first quarter of 2025. The results for the fourth quarter of 2025 are still subject to finalization and may differ from the current preliminary estimates. Investors are advised to consider the uncertainties surrounding these expenses and their potential impact on the company's financial performance.

Jan 13, 2026 17:38:54

Biogen Reports Third Quarter 2025 Financial Results and Guidance

Biogen reported total revenue of $2.5 billion for the third quarter of 2025, marking a 3% increase from the previous year. The company achieved a GAAP diluted earnings per share (EPS) of $3.17, up 19% year-over-year, and a non-GAAP diluted EPS of $4.81, an 18% increase. Growth was driven by a 67% rise in revenue from launch products in Alzheimer's disease, rare diseases, and postpartum depression, with notable sales from LEQEMBI and SKYCLARYS. The company also highlighted progress in its late-stage pipeline programs and provided updates on key clinical trials and product launches.

Biogen updated its financial guidance for the full year 2025, now expecting non-GAAP diluted EPS to be between $14.50 and $15.00, reflecting a stronger underlying business outlook. Total revenue is projected to be approximately flat to increasing by 1% compared to 2024. The company anticipates increased competitive pressures in the ex-U.S. multiple sclerosis market, particularly for TECFIDERA, and plans to invest in research and development to support pipeline expansion. Additionally, Biogen announced recent licensing and acquisition agreements aimed at enhancing its product offerings.

Oct 30, 2025 06:13:59

Biogen Reports $2 Million Expense Impacting Q3 Earnings Per Share

Biogen Inc. anticipates a pre-tax expense of approximately $2 million related to acquired in-process research and development for the third quarter of 2025. This expense is expected to affect both GAAP and non-GAAP net income per diluted share by about $0.01. The company has begun presenting this expense as a separate line item in its financial statements, which includes costs from collaboration and license agreements.

The financial results for the quarter ending September 30, 2025, are still being finalized and may differ from these preliminary estimates. Biogen has noted that it cannot predict future occurrences of such expenses due to their uncertain nature, and investors are advised to consider the potential risks involved as outlined in the company's previous reports.

Oct 14, 2025 16:19:10

Biogen Reports Q2 2025 Financial Results and Guidance Update

Biogen reported total revenue of $2.6 billion for Q2 2025, reflecting a 7% increase year-over-year. The company reported a GAAP diluted EPS of $4.33, an 8% increase, and a Non-GAAP diluted EPS of $5.47, up 4% year-over-year. Key growth drivers included strong sales from Alzheimer's disease treatments, particularly LEQEMBI, which saw U.S. sales of approximately $63 million and global sales of around $160 million. Other notable revenue contributions came from SKYCLARYS and ZURZUVAE, with respective revenues of $130 million and $46 million, indicating significant growth in demand for these products. Biogen also announced advancements in its late-stage pipeline, including the initiation of Phase 3 studies for several treatments in rare diseases.

The company has raised its full-year 2025 guidance, now expecting Non-GAAP diluted EPS between $15.50 and $16.00, up from a previous range of $14.50 to $15.50. Total revenue is expected to remain flat year-over-year at constant currency, an improvement from prior expectations of a mid-single-digit decline. The guidance reflects strong performance in the first half of 2025, although Biogen anticipates increased competitive pressures in the second half, particularly for its multiple sclerosis products in Europe. The company plans to invest in R&D to support its clinical development activities, particularly in rare diseases, while also aiming for significant cost savings through its

Jul 31, 2025 06:13:54

Biogen Reports Estimated Q2 2025 Expenses Impacting Earnings

Biogen Inc. anticipates that its GAAP and non-GAAP results for the second quarter of 2025 will reflect approximately $46 million in acquired in-process research and development expenses. This expense is expected to reduce net income per diluted share by about $0.26. The company has started reporting these expenses as a separate line item in its financial statements, which include costs related to collaboration and license agreements.

The financial results for the quarter ending June 30, 2025, are still being finalized and may differ from the preliminary estimates provided. Biogen has noted that it does not forecast these expenses due to the inherent uncertainties surrounding their occurrence and timing. Investors are advised that the final results will be subject to closing procedures and could vary from the current estimates.

Jul 07, 2025 16:10:34

Biogen Reports Q1 2025 Revenue Growth and Updated Financial Guidance

Biogen announced its first quarter 2025 financial results, reporting total revenue of $2.4 billion, which is a 6% increase compared to the same period last year. The company's GAAP diluted earnings per share (EPS) was $1.64, while the Non-GAAP diluted EPS was $3.02. The results were influenced by a $165 million upfront payment to Stoke Therapeutics, impacting EPS by approximately $0.95. Notably, product revenue increased by 3% at constant currency, with significant contributions from new product launches in Alzheimer's disease and rare diseases. LEQEMBI and SKYCLARYS showed growth in sales, with LEQEMBI generating approximately $96 million globally in the first quarter.

Biogen updated its full-year 2025 financial guidance, projecting Non-GAAP diluted EPS to range from $14.50 to $15.50, reflecting the impact of the Stoke payment and favorable foreign exchange rates. The company anticipates a mid-single digit percentage decline in total revenue for 2025 compared to 2024, primarily due to expected declines in multiple sclerosis product revenue. Biogen's ongoing initiatives, including the

May 01, 2025 06:52:09

Biogen Reports $2.5 Billion Q4 Revenue with Mixed Results

On the downside, Biogen faced a decline in total revenue for the full year 2024, primarily driven by a decrease in multiple sclerosis product sales, which dropped by 7% year-over-year. The company anticipates further revenue decline in 2025, projecting a mid-single digit percentage drop compared to 2024. Moreover, Biogen's collaboration profit-sharing led to a net expense of about $57 million in Q4 2024. The company also announced the discontinuation of several drug development programs, including those for early Alzheimer's and Parkinson's diseases, indicating a strategic shift in their pipeline focus.

Feb 12, 2025 07:06:19

Biogen CFO Retirement Announcement and Successor Appointment

Biogen Inc. announced the upcoming retirement of Michael McDonnell, the Executive Vice President and Chief Financial Officer, effective February 28, 2025. McDonnell has been with Biogen since August 2020 and has played a key role in restructuring the company for sustainable growth, including overseeing strategic acquisitions and promoting financial discipline. The leadership expressed gratitude for his contributions during his tenure, highlighting his mentorship and leadership in the Fit for Growth program.

Robin Kramer, currently the Chief Accounting Officer, will succeed McDonnell as CFO. Kramer, who joined Biogen in 2018, brings extensive experience in finance and has worked closely with McDonnell on the company’s growth initiatives. While the transition is positioned as smooth and beneficial for Biogen's future, the announcement also marks the end of McDonnell's impactful leadership, raising questions about the future direction of the company under new financial leadership.

Oct 30, 2024 16:45:53